UroAlert - GU Oncology Weekly

May 28, 2026

Videos

Peer-to-Peer Clinical Conversations

CORE-008 Cohort B Evaluates Cretostimogene in BCG-Exposed Non-Muscle Invasive Bladder Cancer - Trinity Bivalacqua

Trinity Bivalacqua

Trinity Bivalacqua discusses CORE-008 Cohort B, an enrolling trial evaluating cretostimogene in the BCG-exposed NMIBC space.

ECLIPSE Trial Explores Dosimetry for PSMA-Targeted Therapy in mCRPC - Frankis Almaguel & Jason Hafron

Jason Hafron

Frankis Almaguel presents ECLIPSE trial dosimetry data from 26 metastatic castration-resistant prostate cancer patients using multi-point SPECT CT.

Beyond the Abstracts

Does the Urinary Microbiome Reflect the Bladder-Cancer-Associated Microbiome? Characterizing the Microbiome in Urine and Cancer Tissue in Bladder Cancer - Beyond the Abstract

[99mTc]Tc-Sestamibi SPECT/CT for the Diagnosis of Kidney Tumours: A Multi-Centre Feasibility Study (MULTI-MIBI Study) - Beyond the Abstract

Conference Coverage

AUA 2026: Alvimopan in Patients Undergoing Radical Cystectomy and Urinary Diversion on a Standardized Enhanced Recovery After Surgery Protocol: A Randomized, Double-Blind, Placebo-Controlled Trial

AUA 2026: Comparison between IO–IO and IO–TKI Combination Therapies for Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus

AUA 2026: Evaluating Deep Early Tumor Shrinkage in Metastatic Upper Tract Urothelial Carcinoma Treated with Enfortumab Vedotin plus Pembrolizumab

AUA 2026: Duration of Response to UGN-102 by Age at Baseline Across 3 Clinical Trials in Patients with Recurrent Low Grade Intermediate Risk Bladder Cancer

AUA 2026: TRCG-011: Prospective Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Sustained Release Gemcitabine Docetaxel combination (NDV-01) in High Risk NMIBC: Update with 12-month Complete Response Data

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis.

Proceedings of the first international NMIBC consensus classification meeting.

Diagnostic performance of urinary tumor DNA in urothelial carcinoma: A systematic review and network meta-analysis.

Effective PD-1 checkpoint blockade in bladder cancer model requires tumor-draining lymph nodes and lymphocyte trafficking.

Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.

Artificial Intelligence Remote Patient Monitoring for Predicting Overall Survival for Patients Undergoing Radical Cystectomy for Bladder Cancer: Exploratory Analysis of the Prospective Trial.

Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery.

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.

Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer.

Development and validation of a machine learning model for predicting 30-day major morbidity and mortality following radical cystectomy: An American College of Surgeons National Surgical Quality Improvement Program study.

Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study.

Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guérin.

Detection of Bladder Cancer in Patients with Microscopic Hematuria Using Oncuria-Detect: Results of a Prospective, Multicenter International Study - Beyond the Abstract

Impact of Pelvic Lymph Node Dissection on Oncological Outcomes in Patients with Clinically Staged Non-Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Systematic Review - Beyond the Abstract

Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial Design - Beyond the Abstract

Penile & Urethral Cancers

Neoadjuvant Treatment for Penile Cancer: A Systematic Review of Contemporary Evidence.

Prognostic Significance of Pretreatment Blood-Based Biomarkers in Penile Cancer: A Multicenter Retrospective Study in Japan.

Renal Cancer

Metastatic Patterns and Adverse Histopathologic Features in Advanced Renal Cell Carcinoma: A Five-Year Single-Center Retrospective Pathology Study.

Histologic Heterogeneity of Metastases in Clear Cell Renal Cell Carcinoma with Sarcomatoid Differentiation.

Overdiagnosis in renal cancer: the hidden consequence of modern imaging.

Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial.

Improving Clear Cell Renal Cell Carcinoma Diagnosis: Modified CT Algorithms with Simplified Heterogeneity Scoring.

Two decades of research on drug resistance in renal cell carcinoma.

Bibliometric study on hotspots and trends of immunotherapy for kidney cancer from 2014 to 2024.

Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma.

Association between systemic inflammatory response index and the prognosis of patients with localized and advanced renal cell carcinoma: a systematic review and meta-analysis.

International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinoma.

CT-Based Renal Artery Caliber Change as a Potential Imaging Marker of Treatment Response in Renal Cell Carcinoma; an Exploratory Imaging Study - Beyond the Abstract

Prostate Cancer

PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer.

Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer.

Analytical Validation of MyProstateScore 2.0-Active Surveillance: A Urinary-Based Clinical RT-PCR Prostate Cancer Assay.

Prioritising Data Quality Governance for AI in Prostate Cancer: A Methodological Proof-of-Concept Study Using Neural Networks for Risk Stratification.

Evaluating Oncological Outcomes in Patients with Multiple PiRADS Lesion Treated with Robot-Assisted Radical Prostatectomy for Prostate Cancer: Results from a Large Contemporary Cohort with Centralized MpMRI Evaluation in a High-Volume Center.

Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer.

Impact of frailty on perioperative and oncologic outcomes after robotic radical prostatectomy: a multicenter study with competing risk analysis.

Defining the combinatorial nature of gene modules in prostate cancer underlying lineage plasticity and metastasis.

Early-access Use of Radioligand Therapy in Prostate Cancer.

Adverse pathology and low tumor volume in biopsy Gleason 3 + 4 prostate cancer: Toward safe expansion of active surveillance and focal therapy.

Therapy Optimization in mHSPC: Insights from a Multidisciplinary Uro-Oncology Expert Panel.

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

Bladder activity of different PSMA PET radioligands and impact of furosemide.

Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer.

Focal Signet Ring-Like Prostate Adenocarcinoma Detected on Microultrasound in the Setting of Negative Multiparametric Magnetic Resonance Imaging: A Case Report.

Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) - a phase 2 study: acute safety and quality of life outcomes.

Improving physical activity in men with prostate cancer through wearable devices and online education: Randomized controlled trial.

Baseline PSMA-ligand PET/CT as a predictive biomarker for early progression in metastatic castration-resistant prostate cancer patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy.

Radioligand Therapy Hormone Combinations and the ENZA-p Trial.

Elective Nodal Radiotherapy in Localized Prostate Cancer: A Meta-Analysis.

Partial gland ablation for radio-recurrent prostate cancer: Short-term oncological and functional outcomes.

Frailty and Quality of Life in Low-Income, Uninsured Men with Prostate Cancer.

Racial and ethnic differences in prostate cancer screening outcomes in the United States: A secondary analysis of the prostate, lung, colorectal, and ovarian cancer trial.

Treatment and progression of patients in Sweden with metastatic castration-sensitive prostate cancer.

Transforming postoperative follow-up: telemedicine trends in radical prostatectomy patients.

Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.

Real-World Representation in Prostate Cancer Clinical Trials: Needs and Opportunities.

A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.

Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review - Beyond the Abstract

Identification of Biomarkers Predictive of Successful Salvage Surgery in Prostate-specific Membrane Antigen Positron Emission Tomography-positive Oligorecurrent Prostate Cancer: Results from the BioPoP Trial - Beyond the Abstract

Upper Tract Tumors

Circulating Tumor DNA in Upper Tract Urothelial Carcinoma: A Framework for Precision Perioperative Management.

SOX2-positive upper tract urothelial carcinoma: Clinicopathological characteristics and therapeutic implications.

Renal function outcomes following endoscopic management of upper tract urothelial carcinoma.

Testicular Cancer

Contemporary Perioperative Outcomes of Robotic Retroperitoneal Lymph Node Dissection for Testicular Cancer.

Improving the Understanding of Late Effects of Testicular Cancer in Adolescent and Young Adult Survivors: TRANSCEND-XR.

NFL's Alex Singleton and the Testicular Cancer Detection Gap.

Primary retroperitoneal lymph node dissection for clinical stage II seminoma: Comparative analysis against established paradigms using the National Cancer Data Base.

Adrenal Diseases

Association between remnant cholesterol inflammation index and erectile dysfunction among U.S. adults: a cross-sectional study.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC